CNS Pharmaceuticals Files 10-K/A Amendment

Ticker: CNSP · Form: 10-K/A · Filed: 2025-04-30T00:00:00.000Z

Sentiment: neutral

Topics: amendment, annual-report, pharmaceuticals

TL;DR

CNS Pharmaceuticals filed an amendment to its 2024 10-K, updating Part III. Check for details.

AI Summary

CNS Pharmaceuticals, Inc. filed an amendment (10-K/A) on April 30, 2025, to its annual report for the fiscal year ended December 31, 2024. This amendment specifically addresses Part III of the report. The company, incorporated in Nevada with its principal executive offices in Houston, Texas, operates in the pharmaceutical preparations industry.

Why It Matters

This filing indicates an update or correction to the company's annual report, which could contain important information for investors regarding the company's financial health and strategic direction.

Risk Assessment

Risk Level: medium — Amendments to SEC filings can sometimes indicate previously undisclosed issues or a need for clarification, warranting a medium risk assessment until the specific changes are fully understood.

Key Numbers

Key Players & Entities

FAQ

What specific information is being amended in Part III of the 10-K filing?

The filing indicates that Amendment No. 1 is to Amend Part III of the Form 10-K for the fiscal year ended December 31, 2024. Specific details of the amendment are not provided in this header information.

When was the original 10-K filed, and what is the purpose of this amendment?

The original 10-K was for the fiscal year ended December 31, 2024. This filing, dated April 30, 2025, is Amendment No. 1, specifically to amend Part III.

What is the primary business of CNS Pharmaceuticals, Inc.?

CNS Pharmaceuticals, Inc. operates in the 'PHARMACEUTICAL PREPARATIONS' industry, with the Standard Industrial Classification code 2834.

Where are CNS Pharmaceuticals, Inc.'s principal executive offices located?

The company's principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.

In which U.S. state was CNS Pharmaceuticals, Inc. incorporated?

CNS Pharmaceuticals, Inc. was incorporated in Nevada.

From the Filing

0001683168-25-002998.txt : 20250430 0001683168-25-002998.hdr.sgml : 20250430 20250430163010 ACCESSION NUMBER: 0001683168-25-002998 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250430 DATE AS OF CHANGE: 20250430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 25895906 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 10-K/A 1 cns_10ka1-123124.htm AMENDMENT NO. 1 TO FORM 10-K CNS Pharmaceuticals, Inc. 10-K/A true to Amend Part III 2024 FY 0001729427 0001729427 2024-01-01 2024-12-31 0001729427 2024-06-30 0001729427 2025-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Table of Contents   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549   FORM 10-K/A (Amendment No. 1)   ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the fiscal year ended December 31 , 2024   OR   ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from _________________ to ___________________   Commission File Number: 001-39126   CNS Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter)   Nevada   82-2318545 (State or Other Jurisdiction of Incorporation or Organization)   (I.R.S. Employer Identification No.)   2100 West Loop South , Suite 900 Houston , Texas 77027 (Address of Principal Executive Offices) (Zip Code)   Registrant’s Telephone Number, including Area Code: 800 - 946-9185   Securities registered pursuant to Section 12(b) of the Exchange Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock CNSP The NASDAQ Stock Market LLC   Securities registered pursuant to Section 12(g) of the Act: None   Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes   ☐      No    ☒   Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes   ☐     No    ☒   Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.     Yes    ☒     No   ☐   Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes    ☒     No   ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”

View on Read The Filing